Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.

Bartha E, Solti I, Szabo A, Olah G, Magyar K, Szabados E, Kalai T, Hideg K, Toth K, Gero D, Szabo C, Sumegi B, Halmosi R.

J Cardiovasc Pharmacol. 2011 Oct;58(4):380-91. doi: 10.1097/FJC.0b013e318225c21e.


The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts.

Pálfi A, Tóth A, Kulcsár G, Hantó K, Deres P, Bartha E, Halmosi R, Szabados E, Czopf L, Kálai T, Hideg K, Sümegi B, Tóth K.

J Pharmacol Exp Ther. 2005 Oct;315(1):273-82. Epub 2005 Jun 10.


PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.

Deres L, Bartha E, Palfi A, Eros K, Riba A, Lantos J, Kalai T, Hideg K, Sumegi B, Gallyas F, Toth K, Halmosi R.

PLoS One. 2014 Jul 11;9(7):e102148. doi: 10.1371/journal.pone.0102148. eCollection 2014.


Davallialactone protects against adriamycin-induced cardiotoxicity in vitro and in vivo.

Arunachalam S, Kim SY, Lee SH, Lee YH, Kim MS, Yun BS, Yi HK, Hwang PH.

J Nat Med. 2012 Jan;66(1):149-57. doi: 10.1007/s11418-011-0567-1. Epub 2011 Aug 21.


Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.

Pacher P, Liaudet L, Bai P, Virag L, Mabley JG, Haskó G, Szabó C.

J Pharmacol Exp Ther. 2002 Mar;300(3):862-7.


PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.

Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kálai T, Hideg K, Halmosi R, Sumegi B, Toth K.

Cardiovasc Res. 2009 Aug 1;83(3):501-10. doi: 10.1093/cvr/cvp144. Epub 2009 May 14.


Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice.

Veres B, Radnai B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Sumegi B.

J Pharmacol Exp Ther. 2004 Jul;310(1):247-55. Epub 2004 Mar 3.


Protection against chronic hypoperfusion-induced retinal neurodegeneration by PARP inhibition via activation of PI-3-kinase Akt pathway and suppression of JNK and p38 MAP kinases.

Mester L, Szabo A, Atlasz T, Szabadfi K, Reglodi D, Kiss P, Racz B, Tamas A, Gallyas F Jr, Sumegi B, Hocsak E, Gabriel R, Kovacs K.

Neurotox Res. 2009 Jul;16(1):68-76. doi: 10.1007/s12640-009-9049-6. Epub 2009 Apr 9.


Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.

Bartha E, Kiss GN, Kalman E, Kulcsár G, Kálai T, Hideg K, Habon T, Sumegi B, Toth K, Halmosi R.

J Cardiovasc Pharmacol. 2008 Sep;52(3):253-61. doi: 10.1097/FJC.0b013e3181855cef.


Doxorubicin represses CARP gene transcription through the generation of oxidative stress in neonatal rat cardiac myocytes: possible role of serine/threonine kinase-dependent pathways.

Aihara Y, Kurabayashi M, Tanaka T, Takeda SI, Tomaru K, Sekiguchi KI, Ohyama Y, Nagai R.

J Mol Cell Cardiol. 2000 Aug;32(8):1401-14.


PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

Palfi A, Toth A, Hanto K, Deres P, Szabados E, Szereday Z, Kulcsar G, Kalai T, Hideg K, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

J Mol Cell Cardiol. 2006 Jul;41(1):149-59. Epub 2006 May 23.


Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27.

Venkatakrishnan CD, Tewari AK, Moldovan L, Cardounel AJ, Zweier JL, Kuppusamy P, Ilangovan G.

Am J Physiol Heart Circ Physiol. 2006 Dec;291(6):H2680-91. Epub 2006 Jun 16.


Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts.

Andreone TL, O'Connor M, Denenberg A, Hake PW, Zingarelli B.

J Immunol. 2003 Feb 15;170(4):2113-20.


ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes.

Liu J, Mao W, Ding B, Liang CS.

Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H1956-65. doi: 10.1152/ajpheart.00407.2008. Epub 2008 Sep 5.


Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress.

Wang XY, Yang CT, Zheng DD, Mo LQ, Lan AP, Yang ZL, Hu F, Chen PX, Liao XX, Feng JQ.

Mol Cell Biochem. 2012 Apr;363(1-2):419-26. doi: 10.1007/s11010-011-1194-6. Epub 2011 Dec 28.


Subcellular basis of vitamin C protection against doxorubicin-induced changes in rat cardiomyocytes.

Ludke A, Sharma AK, Bagchi AK, Singal PK.

Mol Cell Biochem. 2012 Jan;360(1-2):215-24. doi: 10.1007/s11010-011-1059-z. Epub 2011 Sep 22.


Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction.

Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virág L, Deb A, Szabó E, Ungvári Z, Wolin MS, Groves JT, Szabó C.

Circulation. 2003 Feb 18;107(6):896-904.


Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27.

Turakhia S, Venkatakrishnan CD, Dunsmore K, Wong H, Kuppusamy P, Zweier JL, Ilangovan G.

Am J Physiol Heart Circ Physiol. 2007 Nov;293(5):H3111-21. Epub 2007 Sep 14.

Supplemental Content

Support Center